Frontiers in Neuroscience
May 23, 2023
Junhong Liu, Yuanyuan Wang, Ke Xia et al.
17 citations
Retracted
Psilocybin, a naturally occurring hallucinogenic component of magic mushrooms, has significant psychoactive effects in both humans and rodents. But the underlying mechanisms are not fully understood. Blood-oxygenation level-dependent (BOLD) functional magnetic resonance imaging (fMRI) is a useful tool in many preclinical and clinical trials to investigate psilocybin-induced changes of brain...
Fortschritte der Neurologie · Psychiatrie
May 19, 2023
Anna Lasch, Timo Schweikert, Eva Dora et al.
1 citation
Zusammenfassung Eine erfolgreiche Therapie psychischer Störungen ist angesichts des häufig vorhandenen Leidensdrucks der Betroffenen sehr wichtig. Da anerkannte pharmazeutische und psychotherapeutische Ansätze leider nicht für alle Patient:innen zur erwünschten Besserung ihres Leidens führen, findet intensive Forschung zu ergänzenden oder alternativen Behandlungsmethoden statt. Besonders...
World Journal of Psychiatry
May 19, 2023
Lakshan N Fonseka, Benjamin K.p. Woo
12 citations
With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression, psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched, rapid improvement in a multitude of psychiatric conditions....
Australian Journal of Chemistry
May 16, 2023
Eliza Milliken, Peter Galettis, Jenny Martin
4 citations
Classic psychedelics such as psilocybin, ketamine and lysergic acid diethylamide (LSD) are 5HT2A serotonin receptor agonists that produce individualised subjective affects. Today, public interest in psychedelic medicine has reached a fervour but the evidence for clinical benefit still lags. Psilocybin and psilocin are tryptophan based alkaloids found worldwide in mushrooms of the genera...
Research Square
May 12, 2023
Gabriel Thorens, Louise Penzenstadler, Leonice Furtado et al.
preprint
Abstract Case report of a patient with GAD and claustrophobia who underwent exposure therapy using psilocybin-assisted psychotherapy. The patient had failed to respond to conventional psychotherapeutic treatment. After three sessions of psilocybin-assisted psychotherapy, the patient experienced a reduction in anxiety and fear associated with closed spaces, elevators, and planes. The protocol...
Translational Psychiatry
May 10, 2023
Sandeep Singh, Alexander Botvinnik, Orr Shahar et al.
54 citations
Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble burying, suggest that psilocybin may be effective in treating obsessive-compulsive disorder. However, the receptor mechanisms implicated in the putative anti-obsessional effect are not clear. On this background, we set out to explore (1) the role of serotonin 2A (5-HT2A) and serotonin...
Cureus
May 7, 2023
Suhwoo Bae, Michael Vaysblat, Ilja Dejanovic et al.
6 citations
Recreational drug use is a significant public health concern in various countries. It is well understood that usage of psychedelics/hallucinogens, such as lysergic acid diethylamide (LSD), ecstasy, phencyclidine (PCP), and psilocybin-containing mushrooms, has increased significantly over the last few decades, particularly in adolescents and young adults, yet the effects of these recreational...
Journal of Psychopharmacology
May 3, 2023
Alain Braillon, Florian Naudet
1 citation
International audience
Australian & New Zealand Journal of Psychiatry
May 3, 2023
Susan L. Rossell, Sally Meikle, M.l. Williams et al.
14 citations
No description available
Biological Psychiatry
May 1, 2023
Scott T Aaronson, Tammy Miller, Samuel Rudow et al.
Background: Despite increasingly re fi ned tools for identi-fying individuals at clinical high-risk for psychosis (CHR-P), less is known about the effectiveness of interventions for CHR-P. The signi fi cant clinical heterogeneity among CHR-P individuals is a notable barrier, suggesting that interventions may need to be personalized during this emerging phase of illness. To address these gaps, the...